SuperCol: Rational design of super-selective and responsive colloidal particles for biomedical applications
Tiny colloidal superheros could have oversized power for diagnosis and treatment
SuperCol will train a new generation of scientists in modern super-resolution microscopy and particle functionalisation for improved colloidal design and nanoscale interfacial control for particle-based biosensing. Colloidal-particle-based materials have shown unique abilities in (bio)sensing and other applications because of their large surface-to-volume ratio and biochemical functionalisation. However, we have had only limited success in controlling the sensing properties and cannot yet realise the sensitivity, selectivity and kinetic control that is achieved by e.g. cellular sensing networks. In order to realise this we need to initiate a paradigm shift and create surfaces with a quantified and rationally designed number, distribution, and activity of receptors. To achieve this, we need to understand the structure-function relation between the loading patterns and the sensing characteristics. At this moment, we do not know: (1) how to accurately visualise individual receptors on colloidal surfaces, (2) how to influence the number, distribution and activity of receptors and (3) how this surface organisation translates to highly desired functionalities such as responsiveness and super-selectivity. Super-resolution imaging, advanced particle surface chemistry and advanced modelling will allow to bridge these gaps. However, the field lacks the human capital that can oversee and bridge these disciplines to advance these approaches and effectively (a) control, (b) visualise and quantify, and (c) rationally design surface-functionality to advance particle-based biomedical applications. SuperCol will train the next generation of researchers to overcome this barrier, and will develop e.g. super-selective biosensors for dengue and cholera, and responsive particles that allow biomolecules to be captured (e.g. inflammation markers) and released (e.g. doxorubicin) on demand.